BioCentury | Nov 9, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

As new therapies designed to cut off sickle cell disease pathology at the root advance through the clinic, the field is moving beyond endpoints centered on pain crises to readouts based on hemoglobin. A single,...
BC Innovations | Nov 13, 2018
Distillery Therapeutics

Cancer

INDICATION: B cell lymphoma Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could enhance the efficacy of BCL-2 inhibitors to treat diffuse large B cell lymphoma (DLBCL). In a DLBCL cell line,...
BC Extra | Dec 15, 2017
Company News

Strigini retiring as Novartis Oncology's CEO

Novartis AG (NYSE:NVS; SIX:NOVN) said Bruno Strigini will retire as CEO of Novartis Oncology by early 2018. He will leave the company's executive committee by Dec. 31. Spokesperson Eric Althoff told BioCentury that Novartis is...
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BC Innovations | May 3, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting BRD4 or CDK7 could help treat diffuse intrinsic pontine glioma (DIPG). In DIPG cells from eight patients, a bromodomain inhibitor tool compound or a CDK7...
BC Innovations | Dec 13, 2016
Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); B cell lymphoma Patient sample, cell culture and mouse studies suggest HDAC inhibitors could help treat patients with B cell precursor ALL expressing gene fusions involving MEF2D . Levels of HDAC9...
BioCentury | May 30, 2016
Emerging Company Profile

Straightening out sickle cell

Imara Inc .'s phosphodiesterase-9 inhibitor, IMR-687 , is a potentially disease-modifying candidate for sickle cell disease that could avoid the toxicities and dosing challenges associated with more advanced products. Sickle cell disease is a genetic disorder...
BC Extra | Apr 12, 2016
Politics & Policy

ICER casts doubt on cost-effectiveness of newer MM drugs

In a draft evidence Kyprolis carfilzomib , Empliciti elotuzumab and Ninlaro ixazomib , all in combination with Revlimid lenalidomide and dexamethasone, "provide an incremental or better net health benefit for both second-line and third-line or subsequent therapy"...
BC Week In Review | Feb 1, 2016
Company News

Novartis sales and marketing update

The U.K.’s NICE issued final guidance recommending Farydak panobinostat from Novartis to treat multiple myeloma (MM) in patients who have received two prior therapies, including Velcade bortezomib and an immunomodulatory agent -- its approved indication....
BC Extra | Jan 27, 2016
Company News

NICE backs five cancer drugs, spurns Cyramza

The U.K.'s NICE recommended a quintet of cancer drugs, including reversing a prior decision on Farydak panobinostat from Novartis AG (NYSE:NVS; SIX:NOVN); however, the agency snubbed stomach cancer compound Cyramza ramucirumab from Eli Lilly and...
Items per page:
1 - 10 of 73